Coric Vlad 4

What Happened

• Coric Vlad, CEO of Biohaven Ltd. (BHVN), received an equity award of 550,000 derivative shares on 2026-02-27. The filing reports an acquisition price of $0.00 (award/grant), and the instrument is recorded as a derivative award rather than an open-market purchase or sale.

Key Details

• Transaction date: February 27, 2026; filing date: March 3, 2026.
• Transaction type/code: A (Award/Grant), recorded as a derivative.
• Shares/units granted: 550,000; acquisition price: $0.00. The filing does not state a dollar value or per-share fair-market value.
• Vesting: The underlying shares vest in four equal installments on February 27 of 2026, 2027, 2028 and 2029, subject to the CEO’s continuous service at each vesting date (footnote from the filing).
• Shares owned after the transaction: not specified in the filing.
• No sale, exercise-for-cash, or immediate disposition of shares is reported here.

Context

• This is a compensation award (equity grant) to an executive, not an open-market purchase or sale. Such grants are common as part of executive pay and vest over time; they do not by themselves indicate a buy/sell signal.
• Because this is a derivative award with scheduled vesting, value will depend on future vesting and the company’s stock price at those times.